# A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment

> **NCT01316094** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 165 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** ASP1941
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01316094
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-18
- **Primary completion:** 2012-11-28
- **Final completion:** 2012-11-28
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01316094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01316094, "A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01316094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*